The emergence of designed multiple ligands for neurodegenerative disorders

Albani, 2010, Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence, J. Alzheimers Dis., 19, 11, 10.3233/JAD-2010-1215 Amenta, 2008, Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction, Curr. Med. Chem., 15, 488, 10.2174/092986708783503203 Andrews, 1996, Venlafaxine: a novel antidepressant that has a dual mechanism of action, Depression, 4, 48, 10.1002/(SICI)1522-7162(1996)4:2<48::AID-DEPR2>3.0.CO;2-B Ankerst, 2005, Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma, J. Asthma., 42, 715, 10.1080/02770900500305748 Barbiero, 2011, Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease, Behav. Brain Res., 216, 186, 10.1016/j.bbr.2010.07.033 Blanchet, 2008, Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice, Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 1243, 10.1016/j.pnpbp.2008.03.024 Bolognesi, 2007, Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease, J. Med. Chem., 50, 4882, 10.1021/jm070559a Bolognesi, 2009, Structure-activity relationships of memoquin: Influence of the chain chirality in the multi-target mechanism of action, Bioorg. Med. Chem. Lett., 19, 4312, 10.1016/j.bmcl.2009.05.087 Bolognesi, 2010, Multitargeted drugs discovery: Balancing anti-amyloid and anticholinesterase capacity in a single chemical entity.Bioorg, Med. Chem. Lett. Bolognesi, 2009, Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks, J. Med. Chem., 52, 7883, 10.1021/jm901123n Bolognesi, 2009, Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease, Neurotherapeutics, 6, 152162, 10.1016/j.nurt.2008.10.042 Bolognesi, 2009, Alzheimer's disease: new approaches to drug discovery, Curr. Opin. Chem. Biol., 13, 303, 10.1016/j.cbpa.2009.04.619 Bolognesi, 2009, MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond, Curr. Pharm. Des., 15, 601, 10.2174/138161209787315585 Bordet, 2006, PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases, Biochem. Soc. Trans., 34, 1341, 10.1042/BST0341341 Breidert, 2002, Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease, J. Neurochem., 82, 615, 10.1046/j.1471-4159.2002.00990.x Cavalli, 2008, Multi-target-directed ligands to combat neurodegenerative diseases, J. Med. Chem., 51, 347, 10.1021/jm7009364 Chen, 2006, The chemical biology of clinically tolerated NMDA receptor antagonists, J. Neurochem., 97, 1611, 10.1111/j.1471-4159.2006.03991.x Chen, 2001, Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease, J. Neurosci., 21, RC143, 10.1523/JNEUROSCI.21-10-j0001.2001 Chen, 2007, Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease, Clin. Ther., 29, 1825, 10.1016/j.clinthera.2007.09.021 Chen, 2009, Cisd2 mediates mitochondrial integrity and life span in mammals, Autophagy, 5, 1043, 10.4161/auto.5.7.9351 Colca, 2004, Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe, Am. J. Physiol. Endocrinol. Metab., 286, E252, 10.1152/ajpendo.00424.2003 Collino, 2006, Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion, Eur. J. Pharmacol., 530, 70, 10.1016/j.ejphar.2005.11.049 Combs, 2000, Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists, J. Neurosci., 20, 558, 10.1523/JNEUROSCI.20-02-00558.2000 Culman, 2007, PPAR-gamma: therapeutic target for ischemic stroke, Trends Pharmacol. Sci., 28, 244, 10.1016/j.tips.2007.03.004 Dall’Igna, 2003, Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity, Br. J. Pharmacol., 138, 1207, 10.1038/sj.bjp.0705185 Dall’Igna, 2004, Caffeine as a neuroprotective adenosine receptor antagonist, Ann. Pharmacother., 38, 717, 10.1345/aph.1D307 Dinamarca, 2008, Release of acetylcholinesterase (AChE) from beta-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice, Chem. Biol. Interact., 175, 142, 10.1016/j.cbi.2008.05.026 Dinamarca, 2010, Amyloid-beta-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Abeta peptide. Implications for the pathogenesis of Alzheimer's disease, Mol. Neurodegener., 5, 4, 10.1186/1750-1326-5-4 Doyle, 1988, Do hybrid drugs offer an additional benefit over pure alpha 1-blockade for hypertensive patients?J, Hypertens. Suppl., 6, S51 Fernandez, H.H., Greeley, D.R., Zweig, R.M., Wojcieszek, J., Mori, A., Sussman, N.M., 2009. Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial. Parkinsonism Relat Disord. Foster, 1990, Therapeutic potential of NMDA receptor antagonists as neuroprotective agents, Prog. Clin. Biol. Res., 361, 301 Gautier, 2003, Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function, Stroke, 34, 2975, 10.1161/01.STR.0000101914.62066.7B Geldenhuys, 2010, Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening, Bioorg. Med. Chem. Lett., 20, 5295, 10.1016/j.bmcl.2010.06.128 Geldenhuys, 2010, Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET, Bioorg. Med. Chem. Lett., 20, 819, 10.1016/j.bmcl.2009.12.088 Geldenhuys, 2007, Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor, Bioorg. Med. Chem., 15, 1525, 10.1016/j.bmc.2006.09.060 Ghosh, 2010, J. Med. Chem., 53, 2114, 10.1021/jm901618d Hao, 2008, Neuroprotection in mice by NGP1-01 after transient focal brain ischemia, Brain Res., 1196, 113, 10.1016/j.brainres.2007.11.075 Hauser, 2008, Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations, Mov. Disord., 23, 2177, 10.1002/mds.22095 Haycox, 2009, Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation, Drugs Aging, 26, 791, 10.2165/11316770-000000000-00000 Heneka, 2005, Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice, Brain, 128, 1442, 10.1093/brain/awh452 Herrine, 1999, Severe hepatotoxicity associated with troglitazone, Ann. Intern. Med., 130, 163, 10.7326/0003-4819-130-2-199901190-00021 Higgins, 2005, Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat, Psychopharmacology (Berl.), 179, 85, 10.1007/s00213-005-2203-9 Honda, 2008, Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders, J. Mol. Cell. Cardiol., 44, 915, 10.1016/j.yjmcc.2008.03.004 Imai, 2010, A possibility of nutriceuticals as an anti-aging intervention: Activation of sirtuins by promoting mammalian NAD biosynthesis, Pharmacol. Res., 62, 42, 10.1016/j.phrs.2010.01.006 Inestrosa, 2008, Amyloid-cholinesterase interactions. Implications for Alzheimer's disease, FEBS J., 275, 625, 10.1111/j.1742-4658.2007.06238.x Jacobson, 2006, Adenosine receptors as therapeutic targets, Nat. Rev. Drug Discov., 5, 247, 10.1038/nrd1983 Jain, 2000, Evaluation of memantine for neuroprotection in dementia, Expert Opin. Investig. Drugs, 9, 1397, 10.1517/13543784.9.6.1397 Jenner, 2009, Adenosine, adenosine A 2A antagonists, and Parkinson's disease, Parkinsonism Relat. Disord., 15, 406, 10.1016/j.parkreldis.2008.12.006 Ji, 2009, Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome, Exp. Neurol., 216, 321, 10.1016/j.expneurol.2008.12.007 Joghataie, 2004, Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence, Parkinsonism Relat. Disord., 10, 465, 10.1016/j.parkreldis.2004.06.004 Kaundal, 2009, Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils, J. Pharmacol. Sci., 109, 361, 10.1254/jphs.08246FP Kemp, 2002, NMDA receptor pathways as drug targets, Nat. Neurosci., 5Suppl, 1039, 10.1038/nn936 Kennedy, 2007, From symptom palliation to disease modification: Implications for dementia care, Prim. Psych., 14, 30 Kiewert, 2006, NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels, Neurochem. Res., 31, 395, 10.1007/s11064-005-9036-0 Kummer, 2008, PPARs in Alzheimer's Disease, PPAR Res., 2008, 403896, 10.1155/2008/403896 Küppers, 2000, Estrogen: a multifunctional messenger to nigrostriatal dopaminergic neurons, J. Neurocytol., 29, 375, 10.1023/A:1007165307652 Lagouge, 2006, Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha, Cell, 127, 1109, 10.1016/j.cell.2006.11.013 Lee, 2009, PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia, Biochem. Biophys. Res. Commun., 380, 17, 10.1016/j.bbrc.2008.12.181 León, 2011, A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-β aggregation and Ca(2+) dyshomeostasis, Curr. Med. Chem., 18, 552, 10.2174/092986711794480186 LeWitt, 2008, Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005), Ann. Neurol., 63, 295, 10.1002/ana.21315 Li, 2008, Antiapoptosis and mitochondrial effect of pioglitazone preconditioning in the ischemic/reperfused heart of rat, Cardiovasc. Drugs Ther., 22, 283, 10.1007/s10557-008-6115-x Li, 2004, Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration, FEBS Lett., 566, 261, 10.1016/j.febslet.2004.04.047 Lin, 2007, Crystal structure of human mitoNEET reveals distinct groups of iron sulfur proteins, Proc. Natl. Acad. Sci. U.S.A., 104, 14640, 10.1073/pnas.0702426104 Lipton, 2006, Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond, Nat. Rev. Drug Discov., 5, 160, 10.1038/nrd1958 Lu, 2008, Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging, J. Agric. Food Chem., 56, 6910, 10.1021/jf8007212 Luna-Medina, 2005, Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation, J. Biol. Chem., 280, 21453, 10.1074/jbc.M414390200 Maia, 2002, Does caffeine intake protect from Alzheimer's disease?, Eur. J. Neurol., 9, 377, 10.1046/j.1468-1331.2002.00421.x Maruyama, 2004, N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor, Neurochem. Int., 44, 393, 10.1016/j.neuint.2003.08.005 Mdzinarishvili, 2005, NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia, Neurosci. Lett., 383, 49, 10.1016/j.neulet.2005.03.042 Millan, 2006, Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application, Pharmacol. Ther., 110, 135, 10.1016/j.pharmthera.2005.11.006 Miranda, 2000, The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease, Prog. Neurobiol., 62, 633, 10.1016/S0301-0082(00)00015-0 Morelli, 2009, Adenosine A2A receptors and Parkinson's disease, Handb. Exp. Pharmacol., 589, 10.1007/978-3-540-89615-9_18 Morphy, 2004, From magic bullets to designed multiple ligands, Drug Discov. Today, 9, 641, 10.1016/S1359-6446(04)03163-0 Morphy, 2005, Designed multiple ligands. An emerging drug discovery paradigm, J. Med. Chem., 48, 6523, 10.1021/jm058225d Olanow, 2009, A double-blind, delayed-start trial of rasagiline in Parkinson's disease, N. Engl. J. Med., 361, 1268, 10.1056/NEJMoa0809335 Paddock, 2007, MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone, Proc. Natl. Acad. Sci. U.S.A., 104, 14342, 10.1073/pnas.0707189104 Patzer, 2008, Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia, Eur. J. Neurosci., 28, 1786, 10.1111/j.1460-9568.2008.06478.x Peng, 2008, l-3-n-Butylphthalide ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells, Neurosci. Lett., 434, 224, 10.1016/j.neulet.2008.01.080 Peng, 2009, L-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloid-beta peptide in rats, Eur. J. Pharmacol., 621, 38, 10.1016/j.ejphar.2009.08.036 Peng, 2010, L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease, J. Neurosci., 30, 8180, 10.1523/JNEUROSCI.0340-10.2010 Peng, 2011, L-3-n-Butylphthalide regulates amyloid precursor protein processing by PKC and MAPK pathways in SK-N-SH cells over-expressing wild type human APP695, Neurosci. Lett., 487, 211, 10.1016/j.neulet.2010.10.025 Peters, 2003, Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice, Biochim. Biophys. Acta, 1632, 80, 10.1016/S1388-1981(03)00065-9 Prediger, 2005, Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors, Neurobiol. Aging, 26, 957, 10.1016/j.neurobiolaging.2004.08.012 Prediger, 2005, Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD) -- the spontaneously hypertensive rat (SHR), Int. J. Neuropsychopharmacol., 8, 583, 10.1017/S1461145705005341 Quinn, 2008, The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B, Br. J. Pharmacol., 154, 226, 10.1038/bjp.2008.78 Rammes, 2001, The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanesantagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner, Neurosci. Lett., 306, 81, 10.1016/S0304-3940(01)01872-9 Reisberg, 2003, Memantine in moderate-to-severe Alzheimer's disease, N. Engl. J. Med., 348, 1333, 10.1056/NEJMoa013128 Rennings, 2009, Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome, Eur. Heart J. Riederer, 2004, Monoamine oxidase-B inhibition in Alzheimer's disease, Neurotoxicology, 25, 271, 10.1016/S0161-813X(03)00106-2 Roecklein, 2007, Fluorofelbamate, Neurotherapeutics, 4, 97, 10.1016/j.nurt.2006.11.015 Rook, 2010, Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents, J. Med. Chem., 53, 3611, 10.1021/jm1000024 Sagi, 2003, Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor, J. Neurochem., 86, 290, 10.1046/j.1471-4159.2003.01801.x Saluja, 2001, PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture, Glia, 33, 191, 10.1002/1098-1136(200103)33:3<191::AID-GLIA1018>3.0.CO;2-M Saura, 1994, Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography, Neuroscience, 62, 15, 10.1016/0306-4522(94)90311-5 Schapira, 2008, Drug selection and timing of initiation of treatment in early Parkinson's disease, Ann. Neurol., 64, S47 Shachar, 2004, Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats, Neuropharmacology, 46, 254, 10.1016/j.neuropharm.2003.09.005 Shimazu, 2005, A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia, Stroke, 36, 353, 10.1161/01.STR.0000152271.21943.a2 Song, 2008, Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation, Eur. J. Neurosci., 28, 1989, 10.1111/j.1460-9568.2008.06498.x Sramek, 1999, Recent developments in the drug treatment of Alzheimer's disease, Drugs Aging, 14, 359, 10.2165/00002512-199914050-00004 Van Boxtel, 2003, The effects of habitual caffeine use on cognitive change: a longitudinal perspective, Pharmacol. Biochem. Behav., 75, 921, 10.1016/S0091-3057(03)00171-0 Van der Schyf, 2011, The use of multi-target drugs in the treatment of neurodegenerative diseases, Expert Rev. Clin. Pharmacol., 4, 293, 10.1586/ecp.11.13 Van der Schyf, 2007, Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties, Curr. Alzheimer Res., 4, 522, 10.2174/156720507783018226 Van der Schyf, 1986, Characterization of NGP 1-01, an aromatic polycyclic amine, as a calcium antagonist, Pharmacol. Res. Commun., 18, 407, 10.1016/0031-6989(86)90162-1 Weinreb, 2008, The neuroprotective mechanism of action of the multimodal drug ladostigil, Front Biosci., 13, 5131, 10.2741/3069 Weinreb, 2007, Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy, Ann. N.Y. Acad. Sci., 1122, 155, 10.1196/annals.1403.011 Weinreb, 2008, The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity, Chem. Biol. Interact., 175, 318, 10.1016/j.cbi.2008.05.038 Weinreb, 2009, Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs, Neurotherapeutics, 6, 163, 10.1016/j.nurt.2008.10.030 Weinstock, 2009, Ladostigil prevents age-related glial activation and spatial memory deficits in rats, Neurobiol. Aging Wiley, 2007, MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity, Proc. Natl. Acad. Sci. U.S.A., 104, 5318, 10.1073/pnas.0701078104 Wiley, 2007, The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster, J. Biol. Chem., 282, 23745, 10.1074/jbc.C700107200 Wong, 2010, The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action, Pharmacol. Ther., 126, 173, 10.1016/j.pharmthera.2010.02.001 Wu, 2009, Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation, Circulation, 119, 1124, 10.1161/CIRCULATIONAHA.108.812537 Xi, 2009, Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore, Eur. J. Pharmacol., 604, 111, 10.1016/j.ejphar.2008.12.024 Yan, 2003, Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease, J. Neurosci., 23, 7504, 10.1523/JNEUROSCI.23-20-07504.2003 Yi, 2008, PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms, Brain Res., 1244, 164, 10.1016/j.brainres.2008.09.074 Yogev-Falach, 2002, Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline, FASEB J., 16, 1674, 10.1096/fj.02-0198fje Youdim, 2005, Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition, J. Neurosci. Res., 79, 172, 10.1002/jnr.20350 Youdim, 2005, CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases, J. Neural. Transm., 112, 519, 10.1007/s00702-004-0214-z Youdim, 2005, Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders, Trends Pharmacol. Sci., 26, 27, 10.1016/j.tips.2004.11.007 Youdim, 2005, Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases, Mech. Ageing Dev., 126, 317, 10.1016/j.mad.2004.08.023 Youdim, 2004, A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease, Neurology, 63, S32, 10.1212/WNL.63.7_suppl_2.S32 Youdim, 2007, Monoamine oxidase A and B inhibitors in Parkinson's disease, Handb. Clin. Neurol., 84, 93, 10.1016/S0072-9752(07)84034-6 Yu, 2010, Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system, Neuropathol. Appl. Neurobiol., 10.1111/j.1365-2990.2010.01107.x Zdanys, 2008, A systematic review of off-label uses of memantine for psychiatric disorders, Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 1362, 10.1016/j.pnpbp.2008.01.008 Zecca, 2004, Iron, brain ageing and neurodegenerative disorders, Nat. Rev. Neurosci., 5, 863, 10.1038/nrn1537 Zheng, 2005, Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases, Bioorg. Med. Chem., 13, 773, 10.1016/j.bmc.2004.10.037 Zheng, 2009, Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's Therapy, J. Med. Chem., 52, 4095, 10.1021/jm900504c Zheng, 2005, Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons, Biochem. Pharmacol., 70, 1642, 10.1016/j.bcp.2005.09.003 Zheng, 2010, Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy, ACS Chem. Biol., 5, 603, 10.1021/cb900264w Zhu, 2008, Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration, J. Neurochem., 105, 1970, 10.1111/j.1471-4159.2008.05330.x Zimmermann, 2007, Multi-target therapeutics: when the whole is greater than the sum of the parts, Drug Discov. Today, 12, 34, 10.1016/j.drudis.2006.11.008